These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 27518403)

  • 21. Lymphoblastoid interferon alfa-n1 improves the long-term response to a 6-month course of treatment in chronic hepatitis C compared with recombinant interferon alfa-2b: results of an international randomized controlled trial. Clinical Advisory Group for the Hepatitis C Comparative Study.
    Farrell GC; Bacon BR; Goldin RD
    Hepatology; 1998 Apr; 27(4):1121-7. PubMed ID: 9537453
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A pilot double-blind, randomized, and placebo-controlled study of orally administered IFN-alpha-n1 (Ins) in pediatric patients with measles.
    Lecciones JA; Abejar NH; Dimaano EE; Bartolome R; Cinco S; Mariano N; Yerro ME; Cobar S; Fuggan B
    J Interferon Cytokine Res; 1998 Sep; 18(9):647-52. PubMed ID: 9781802
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial.
    Jacobson IM; Dore GJ; Foster GR; Fried MW; Radu M; Rafalsky VV; Moroz L; Craxi A; Peeters M; Lenz O; Ouwerkerk-Mahadevan S; De La Rosa G; Kalmeijer R; Scott J; Sinha R; Beumont-Mauviel M
    Lancet; 2014 Aug; 384(9941):403-13. PubMed ID: 24907225
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Interferon alpha-2b with and without ribavirin in the treatment of hepatitis B e antigen-positive chronic hepatitis B: a randomized study.
    Liu CJ; Lai MY; Chao YC; Liao LY; Yang SS; Hsiao TJ; Hsieh TY; Lin CL; Hu JT; Chen CL; Chen PJ; Kao JH; Chen DS
    Hepatology; 2006 Apr; 43(4):742-9. PubMed ID: 16557544
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy, safety, and immunogenicity of an enterovirus 71 vaccine in China.
    Zhu F; Xu W; Xia J; Liang Z; Liu Y; Zhang X; Tan X; Wang L; Mao Q; Wu J; Hu Y; Ji T; Song L; Liang Q; Zhang B; Gao Q; Li J; Wang S; Hu Y; Gu S; Zhang J; Yao G; Gu J; Wang X; Zhou Y; Chen C; Zhang M; Cao M; Wang J; Wang H; Wang N
    N Engl J Med; 2014 Feb; 370(9):818-28. PubMed ID: 24571754
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial.
    Manns M; Marcellin P; Poordad F; de Araujo ES; Buti M; Horsmans Y; Janczewska E; Villamil F; Scott J; Peeters M; Lenz O; Ouwerkerk-Mahadevan S; De La Rosa G; Kalmeijer R; Sinha R; Beumont-Mauviel M
    Lancet; 2014 Aug; 384(9941):414-26. PubMed ID: 24907224
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Randomized, controlled pharmacokinetic and pharmacodynamic evaluation of albinterferon in patients with chronic hepatitis B infection.
    Colvin RA; Tanwandee T; Piratvisuth T; Thongsawat S; Hui AJ; Zhang H; Ren H; Chen PJ; Chuang WL; Sobhonslidsuk A; Li R; Qi Y; Praestgaard J; Han Y; Xu J; Stein DS;
    J Gastroenterol Hepatol; 2015 Jan; 30(1):184-91. PubMed ID: 24995515
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of combination therapy with ribavirin and high-dose interferon-alpha2b for 24 weeks in chronic hepatitis C.
    Abe S; Narita R; Oto T; Tabaru A; Otsuki M
    J Gastroenterol Hepatol; 2006 Jan; 21(1 Pt 2):308-12. PubMed ID: 16460492
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pegylated interferon-alpha2b plus ribavirin: an efficacious and well-tolerated treatment regimen for patients with hepatitis C virus related histologically proven cirrhosis.
    Roffi L; Colloredo G; Pioltelli P; Bellati G; Pozzpi M; Parravicini P; Bellia V; Del Poggio P; Fornaciari G; Ceriani R; Ramella G; Corradi C; Rossini A; Bruno S;
    Antivir Ther; 2008; 13(5):663-73. PubMed ID: 18771050
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Effect of reducing injection on HFMD in children: a randomized controlled trial].
    Mu YP; Chen XR; Zhang AJ
    Zhongguo Zhong Xi Yi Jie He Za Zhi; 2011 Sep; 31(9):1209-12. PubMed ID: 22013797
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phase II trial of interleukin 2, interferon alpha, and 5-fluorouracil in metastatic renal cell cancer: a cytokine working group study.
    Dutcher JP; Logan T; Gordon M; Sosman J; Weiss G; Margolin K; Plasse T; Mier J; Lotze M; Clark J; Atkins M
    Clin Cancer Res; 2000 Sep; 6(9):3442-50. PubMed ID: 10999727
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and tolerability of pegylated interferon-alpha2a plus ribavirin versus pegylated interferon-alpha2b plus ribavirin in treatment-naive chronic hepatitis C patients.
    Lee S; Kim IH; Kim SH; Kim SW; Lee SO; Lee ST; Kim DG; Lee CS; Choi CS; Cho EY; Kim HC
    Intervirology; 2010; 53(3):146-53. PubMed ID: 20068348
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Acyclovir in the treatment of hand-foot-and-mouth disease.
    Shelley WB; Hashim M; Shelley ED
    Cutis; 1996 Apr; 57(4):232-4. PubMed ID: 8727772
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Controlled release recombinant human interferon-α2b for treating patients with chronic hepatitis C genotype 1: a phase 2a clinical trial.
    Dzyublyk I; Yegorova T; Moroz L; Popovych O; Zaytsev I; Miroshnichenko V; Kromminga A; Wilkes MM; van Hoogdalem EJ; Humphries JE
    J Viral Hepat; 2011 Apr; 18(4):271-9. PubMed ID: 20367790
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pegylated interferon {alpha}2a plus ribavirin versus pegylated interferon {alpha}2b plus ribavirin for the treatment of chronic hepatitis C in HIV-infected patients.
    Berenguer J; González-García J; López-Aldeguer J; Von-Wichmann MA; Quereda C; Hernando A; Sanz J; Tural C; Ortega E; Mallolas J; Santos I; Miralles P; Montes ML; Bellón JM; Esteban H;
    J Antimicrob Chemother; 2009 Jun; 63(6):1256-63. PubMed ID: 19363085
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and safety of peginterferon-alpha2b and ribavirin combination therapy in children with chronic hepatitis C infection.
    Jara P; Hierro L; de la Vega A; Díaz C; Camarena C; Frauca E; Miños-Bartolo G; Díez-Dorado R; de Guevara CL; Larrauri J; Rueda M
    Pediatr Infect Dis J; 2008 Feb; 27(2):142-8. PubMed ID: 18174875
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Combination therapy with thymosin alpha1 and interferon for the treatment of chronic hepatitis C infection: a randomized, placebo-controlled double-blind trial.
    Sherman KE; Sjogren M; Creager RL; Damiano MA; Freeman S; Lewey S; Davis D; Root S; Weber FL; Ishak KG; Goodman ZD
    Hepatology; 1998 Apr; 27(4):1128-35. PubMed ID: 9537454
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Temozolomide in combination with interferon alpha-2b in patients with metastatic melanoma: a phase I dose-escalation study.
    Agarwala SS; Kirkwood JM
    Cancer; 2003 Jan; 97(1):121-7. PubMed ID: 12491513
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Successful treatment with peginterferon alfa-2b of HBeAg-positive HBV non-responders to standard interferon or lamivudine.
    Flink HJ; Hansen BE; Heathcote EJ; Feinman SV; Simsek H; Karayalcin S; Mach T; Leemans WF; de Man RA; Verhey E; Schalm SW; Janssen HL;
    Am J Gastroenterol; 2006 Nov; 101(11):2523-9. PubMed ID: 17029610
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Safety, Tolerability, Bioavailability, and Biological Activity of Inhaled Interferon-α2b in Healthy Adults: The IN
    Garcia-Huidobro D; Iturriaga C; Perez-Mateluna G; Fajuri P; Severino N; Urzúa M; Fraga JP; de la Cruz J; Poli C; Castro-Rodríguez JA; Fish E; Borzutzky A;
    Clin Drug Investig; 2023 Jun; 43(6):447-461. PubMed ID: 37347370
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.